The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial prospector update: A point of care automated clinical trials matching application.
 
David Lawrence Bajor
Research Funding - Apexigen; Roche/Genentech; Seagen; Tesaro
 
Neelesh Sharma
Employment - Novartis
Stock and Other Ownership Interests - Arena Pharma; Arena Pharma; AVEO; AVEO; Aviragen Therapeutics; Aviragen Therapeutics; Edge Therapeutics, Inc.; Edge Therapeutics, Inc.; Edge Therapeutics, Inc.; GalMed Pharmacueticals; GalMed Pharmacueticals; GalMed Pharmacueticals; Idera; Idera; Idera; Idera; Immune Pharmaceuticals; Immune Pharmaceuticals; Immune Pharmaceuticals; Immune Pharmaceuticals; ImmunoCellular Therapeutics; ImmunoCellular Therapeutics; ImmunoCellular Therapeutics; ImmunoCellular Therapeutics; Merrimack; Merrimack; Merrimack; Merrimack; Opexa; Opexa; Opexa; Opexa; Opexa; Peregrine Pharmaceuticals; Peregrine Pharmaceuticals; Peregrine Pharmaceuticals; Peregrine Pharmaceuticals; Peregrine Pharmaceuticals; Rockwell Medical; Rockwell Medical; Rockwell Medical; Rockwell Medical; Rockwell Medical
Consulting or Advisory Role - Bionest Partner; C1 Consulting; LEK
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Incuron (Inst); NanoCarrier (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Janssen Oncology; Merck; Novartis; Sanofi
 
Mital Shirish Patel
No Relationships to Disclose
 
GQ Zhang
No Relationships to Disclose
 
Patrick Mergler
Consulting or Advisory Role - Carevive Systems
Patents, Royalties, Other Intellectual Property - Utility Patent, US application 14/988,132 (Pending). "Systems and Methods for matching patients with clinical trials"; Utility Patent, US application 15/625,697 (pending). "Monitoring and evaluating patient reactions to medications"
 
Shiqiang Tao
No Relationships to Disclose
 
Saroj Sigdel
Patents, Royalties, Other Intellectual Property - US application 15/625, 697 - Pending. "Monitoring and Evaluating Patient Reactions to Medications"
 
Sarah Fulton
No Relationships to Disclose
 
Jessica Surdam
No Relationships to Disclose
 
Neal J. Meropol
Employment - Flatiron Health
Research Funding - Genomic Health
Patents, Royalties, Other Intellectual Property - US Patent (20020031515): Methods of therapy for cancers characterized by over expression of the HER2 receptor protein; US Patent Office “Systems and methods for matching patients with clinical trials.” (Cui, Mergler, Meropol, Tao, and Guo-Qiang Zhang). Patent pending, filed January 5, 2016. 14/988,132
Travel, Accommodations, Expenses - Flatiron Health